The antiproliferative effects of thioalbamide were evaluated over a wide range of breast cancer cell lines characterized by differences in the status of the three main receptors conventionally used for breast cancer subtyping: estrogen receptor (ER), progesterone receptor (PR), and human epithelial receptor 2 (HER2) [17]. The gene discussed is ESR1; the disease is breast carcinoma.